ABOUT EVENT
Welcome to the 2024 ADC Pharmacokinetics & Clinical Pharmacology Summit
With the release of the FDA’s Project Optimus and the evolving clinical pharmacology guidelines for ADCs, the importance of selecting the optimal clinical dose that balances safety and efficacy had never been more clear.
As the ‘small molecule’ mindset shifts to acknowledge the complexity of ADCs, the summit focused on the strategic mindset of integrating clinical pharmacology and modeling and simulation into efficient ADC development.
Bringing together a highly focused audience comprising of those working in clinical pharmacology, pharmacokinetics, pharmacometrics, modelling and bioanalysis, enabled unparalleled information sharing and brainstorming for those across the entire ADC landscape to allowing attendees you to find the right dosage the first time of asking.
You Missed The Opportunity to...
Leverage advancements in PK modeling to better predict the pharmacokinetic profiles of ADCs to optimize dosing strategies, predict patient variability, and improve therapeutic outcomes by ensuring the right balance between efficacy and safety
Gain insights into how others are approaching their preclinical and translational strategy for novel ADCs, gaining early establishment of a clear mechanistic link between ADC design and PK profile leading to safer and more effective ADC therapies
Navigate regulatory guidance, including how others are carrying out dose optimization in line with Project Optimus and recently updated FDA guidance, and anticipate how clinical strategy will need to be evolved in the future
Uncover practical insights from real-world case studies and clinical trial, highlighting successful ADC development programs and lessons learned from past challenges
Join our deep-dive workshops to brainstorm on some of the key challenges in ADCs like bioanalytical strategy and optimisation of dosing in combination approaches
Who Did You Miss?
A highly focused audience comprising those working in clinical pharmacology, pharmacokinetics, pharmacometrics, modelling and bioanalysis will enable unparalleled information sharing and brainstorming for those across the entire ADC landscape including large pharma, biotech, and modelling and bioanalytical providers.
What Your Peers Have to Say:
"At such meeting we can share and discuss different strategies and solutions in early ADC development”
- Heidelberg Pharma
"ADCs are entering a new era that harnesses payloads with specific mechanisms of action beyond pan-cytotoxicity. This makes ADCs even more complex, further emphasizing the need for early establishment of a clear mechanistic link between ADC design, pharmacokinetics, and desired pharmacodynamics”
- Novartis
"It was a great opportunity to exchange with peers in the field of ADC development and with experts in the field”
- Mablink
"Excellent opportunity to hear about recent advances in all areas of ADC development. The quality of the presenters and the information was excellent. I enjoyed meeting with former colleagues and new people”
- Daiichi Sankyo